sarpogrelate has been researched along with Peripheral Arterial Diseases in 7 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events." | 6.61 | Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials. ( Li, J; Liao, L; Lu, Y; Xie, J; Yu, Q, 2019) |
| "Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD)." | 5.22 | Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study. ( Ahn, YK; Chae, IH; Chang, KY; Cho, BR; Cho, DK; Choi, D; Choi, S; Chun, K; Han, KR; Hong, BK; Jin, HY; Kang, W; Kim, DI; Kim, DW; Kim, SH; Kim, YJ; Lee, HC; Lee, JW; Lee, NH; Lee, S; Lee, SR; Park, CG; Pyun, W; Shin, JH; Yu, CW, 2016) |
| "The effect of the prostaglandin I2 analog, beraprost sodium (BPS), on hemodialysis (HD) patients with peripheral arterial disease (PAD) has not been fully elucidated." | 5.19 | Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. ( Hidaka, S; Kobayashi, S; Kondoh, M; Miyaji, T; Moriya, H; Nakazawa, R; Ohtake, T; Sato, M, 2014) |
| " Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months." | 2.84 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017) |
| "Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events." | 2.61 | Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials. ( Li, J; Liao, L; Lu, Y; Xie, J; Yu, Q, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Han, A | 1 |
| Lee, T | 1 |
| Lee, J | 2 |
| Song, SW | 1 |
| Lee, SS | 1 |
| Jung, IM | 1 |
| Kang, JM | 1 |
| Gwon, JG | 1 |
| Yun, WS | 1 |
| Cho, YP | 1 |
| Ko, H | 1 |
| Park, YJ | 1 |
| Min, SK | 2 |
| Lu, Y | 1 |
| Li, J | 1 |
| Xie, J | 1 |
| Yu, Q | 1 |
| Liao, L | 1 |
| Ahn, S | 1 |
| Ha, J | 1 |
| Min, SI | 1 |
| Kim, SY | 1 |
| Cho, MJ | 1 |
| Cho, S | 1 |
| Ohtake, T | 2 |
| Sato, M | 1 |
| Nakazawa, R | 1 |
| Kondoh, M | 1 |
| Miyaji, T | 1 |
| Moriya, H | 2 |
| Hidaka, S | 2 |
| Kobayashi, S | 2 |
| Lee, HC | 1 |
| Lee, SR | 1 |
| Han, KR | 1 |
| Yu, CW | 1 |
| Park, CG | 1 |
| Ahn, YK | 1 |
| Jin, HY | 1 |
| Kim, DW | 1 |
| Cho, DK | 1 |
| Choi, S | 1 |
| Kim, SH | 1 |
| Chang, KY | 1 |
| Lee, S | 1 |
| Pyun, W | 1 |
| Lee, NH | 1 |
| Kang, W | 1 |
| Hong, BK | 1 |
| Cho, BR | 1 |
| Chae, IH | 1 |
| Shin, JH | 1 |
| Chun, K | 1 |
| Kim, DI | 1 |
| Lee, JW | 1 |
| Kim, YJ | 1 |
| Choi, D | 1 |
| Soga, Y | 1 |
| Shintani, Y | 1 |
| Hamasaki, T | 1 |
| Tomoi, Y | 1 |
| Takaoka, J | 1 |
| Suematsu, N | 1 |
| Yokoi, H | 1 |
| Ando, K | 1 |
| Iwagami, M | 1 |
| Isshiki, R | 1 |
| Tsutsumi, D | 1 |
| Mochida, Y | 1 |
| Ishioka, K | 1 |
| Oka, M | 1 |
| Maesato, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606] | Phase 4 | 272 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sarpogrelate and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Ankle Brachial Index; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; P | 2019 |
6 trials available for sarpogrelate and Peripheral Arterial Diseases
| Article | Year |
|---|---|
A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.
Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therapy, Combination; Femoral Artery; Humans | 2023 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con | 2017 |
Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
Topics: Aged; Aged, 80 and over; Cilostazol; Epoprostenol; Female; Heart Rate; Humans; Male; Microcirculatio | 2014 |
Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study.
Topics: Aged; Arteries; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Peri | 2016 |
Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Endovascular Procedures; Female; Femoral Artery; Huma | 2017 |
Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.
Topics: Aged; Blood Pressure; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lower Extremity; M | 2013 |